Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 crossover study of single-dose TD-4208 in COPD
ACTRN12611000482965Phase 2Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2 trial of revefenacin in chronic obstructive pulmonary disease (COPD), sponsored by Theravance Biopharma, Inc. Primary endpoint: Change in peak forced expiratory volume in one second relative to baseline. Started May 2011; status: completed.
02
Drugs
revefenacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ACTRN12611000482965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000482965.